Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Obesity drugs in clinical development.

Jason C G Halford1

  • 1University of Liverpool, Kissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, Eleanor Rathbone Building, Bedford Street South, Liverpool, UK. j.c.g.halford@liverpool.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|April 22, 2006
PubMed
Summary

Several new anti-obesity medications are in development, targeting different mechanisms like appetite control and fat absorption. Rimonabant is the furthest along in clinical trials, nearing completion of phase III. This review details promising obesity drug candidates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Evidence, controversies, and research priorities regarding Low- and No-Calorie Sweeteners (LNCS) in Latin America - Results of the First Latin American Scientific Forum on LNCS].

Nutricion hospitalaria·2026
Same author

Effects of Non-Nutritive Sweeteners and Sweet Taste Exposure on Weight Management, Biomarkers of Health and Sweet Taste Preference-A Review of the Evidence from Recent European Consortia Studies.

Nutrients·2026
Same author

Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy.

International journal of obesity (2005)·2026
Same author

Genetic and Environmental Influences on Free Sugar and Nonnutritive Sweetener Intake in Toddlerhood and Middle Childhood Using Data from the Gemini Twin Cohort: Findings from the SWEET Project.

The Journal of nutrition·2026
Same author

Acute and Prolonged Effects of Sweeteners and Sweetness Enhancers on Postprandial Appetite Sensations, Palatability, and Ad Libitum Energy Intake in Humans: A SWEET Sub-Study.

Nutrients·2026
Same author

The Association Between Affect and Adiposity in Childhood and Adolescence: A Systematic Review.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2025

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Obesity is a complex metabolic disorder with limited effective long-term treatments.
  • Current anti-obesity drug development focuses on diverse mechanisms of action.
  • Several novel therapeutic agents are progressing through clinical trials.

Purpose of the Study:

  • To review prominent anti-obesity drugs currently in clinical development.
  • To provide an overview of therapeutic candidates targeting various pathways involved in weight regulation.
  • To highlight the progress of novel obesity pharmacotherapies.

Main Methods:

  • Review of clinical development pipelines for anti-obesity agents.
  • Categorization of drugs based on their mechanism of action (central, peripheral, fat absorption, metabolic).

Related Experiment Videos

  • Summary of drug candidates including radafaxine, rimonabant, APD-356, oleoyl-estrone, GLP-1 agonists, PYY analogues, amylin analogues, lipase inhibitors, and AOD-9604.

    • Main Results:

    • Multiple drug classes are under investigation, including centrally-acting agents, peripheral satiety signal modulators, fat absorption blockers, and agents promoting adipose tissue breakdown.
    • Rimonabant, an endocannabinoid antagonist, has reached Phase III clinical trials, indicating significant progress.
    • Other notable candidates include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., exenatide, liraglutide) and novel lipase inhibitors (e.g., cetilistat).

    Conclusions:

    • The landscape of anti-obesity pharmacotherapy is expanding with diverse drug candidates.
    • Targeting various physiological pathways offers potential for effective weight management strategies.
    • Continued clinical development is crucial to bring these novel anti-obesity therapies to patients.